Axsome Therapeutics, Inc.
AXSM · NASDAQ
Company research
Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a New York City-based biopharmaceutical company founded in 2012 by Dr. Herriot Tabuteau, focused on developing and commercializing novel therapies for central nervous system (CNS) disorders with limited treatment options. The company has successfully transitioned from a clinical-stage biotech into a commercial-stage enterprise, highlighted by the FDA approval of Auvelity for major depressive disorder (MDD) in 2022, which generated over $507 million in net sales in 2025, contributing to a record total net product revenue of approximately $638.5 million for the year. Axsome's commercial portfolio also includes Sunosi for excessive daytime sleepiness and the recently launched Symbravo for acute migraine treatment, while its pipeline features promising candidates such as AXS-05 for Alzheimer's disease agitation and AXS-12 for narcolepsy. The company leverages proprietary technologies, including its MoSEIC drug solubility platform and a digital-centric commercialization model, to advance a broad pipeline efficiently while targeting cash flow positivity by late 2026 or early 2027.
Research reports
Comprehensive single‑stock report arguing Axsome is one of the best‑executing commercial-stage neuroscience names, with a de‑risked Auvelity franchise, long-dated IP, and strong growth, but trading at a demanding valuation that already prices in much of management’s aggressive peak-sales narrative; the author’s explicit verdict is “HOLD / accumulate-on-weakness,” stressing that quality is high but the margin of safety at current levels is tight and outcomes hinge on Alzheimer’s agitation launch quality and margin conversion.
Flash (StockSentinel AI Research Platform) · May 3, 2026Axsome Therapeutics, Inc. (AXSM) Stock Research ReportDeep, multi-section HTML research report framing Axsome as a “neuroscience growth powerhouse,” highlighting 57% year‑over‑year Q1 2026 revenue growth, Auvelity’s April 2026 FDA approval for Alzheimer’s agitation as a major inflection, >90% gross margins, and long exclusivity into the late 2030s–2040s, and presenting scenario analysis where base and high cases imply large upside with risks centered on Alzheimer’s launch execution, PBM pressure, and pipeline outcomes but overall positioning the stock as a high‑conviction CNS platform investment.
Ainvest (open-access AI-driven Equity Analysis Site) · August 3, 2025Axsome Therapeutics (AXSM): Is Now the Time to Buy After a Strong Q2 Earnings Beat?Article-length investment analysis discussing Axsome’s Q2 2025 net product revenue of about $150 million with 72% year‑over‑year growth driven mainly by Auvelity and Sunosi, outlining late-stage CNS pipeline catalysts (AXS‑05 for Alzheimer’s agitation, AXS‑12 and AXS‑14, solriamfetol label expansions), and concluding that despite a high EV/revenue multiple and ongoing net losses, the stock is an attractive high‑risk, high‑reward buy for 3–5‑year investors willing to tolerate volatility and execution risk around regulatory events and competition.